Coloplast’s Next Generation Inflatable Penile Prosthesis Approved by the FDA – can help millions of men

Coloplast announced FDA approval of Titan Prime, its next-generation inflatable penile prosthesis (IPP) designed to treat severe erectile dysfunction affecting approximately 30 million men in the US. The device features proprietary Bioflex polymer technology offering greater strength and durability than silicone competitors, with improved comfort and concealability. Titan Prime will be available in the U.S. starting in late 2026 through a phased launch.

06/03/2026, 9:00 AM • GlobeNewswire

Wound Irrigation Systems Market to Skyrocket USD 430.05 Million by 2035 as Chronic Wound Cases and Surgical Volumes Rise Worldwide | SNS Insider

The global wound irrigation systems market is projected to grow from USD 307.87 million in 2025 to USD 430.05 million by 2035, with a CAGR of 3.55%. Growth is driven by rising chronic wound prevalence, increased surgical volumes, and innovations in pulsatile lavage systems. North America leads with 40% market share, while Asia Pacific shows the fastest growth at 4.7% CAGR. Manual systems currently dominate with 53% market share, though battery-operated systems are expected to grow fastest.

06/03/2026, 7:00 AM • GlobeNewswire

Coloplast A/S - Selskabsmeddelelse nr. 05/2026 - Regnskabsmeddelelse, 1. halvår 2025/26

Coloplast delivered 6% organic growth in H1 2025/26 with 5% EBIT growth in constant currencies. Strong performance in Chronic Care and Interventional Urology was offset by challenges in Wound & Tissue Repair. The company took a 3.0 billion DKK goodwill writedown on Kerecis due to slower-than-expected market recovery in ambulatory wound care, and revised FY 2025/26 guidance to 5-6% organic growth.

05/12/2026, 1:30 AM • GlobeNewswire

Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26

Coloplast reported H1 2025/26 organic revenue growth of 6% and EBIT growth of 5% in constant currencies. Strong performance in Chronic Care and Interventional Urology was offset by challenges in Wound & Tissue Repair, particularly Kerecis which faced significant Medicare reimbursement headwinds. The company recognized a DKK 3.0 billion impairment loss on Kerecis goodwill and revised FY 2025/26 guidance to reflect slower market recovery in the skin substitutes out-patient setting.

05/12/2026, 1:30 AM • GlobeNewswire

Coloplast Receives Innovative Technology Contract from Vizient for Biatain® Silicone Fit

Coloplast has received an Innovative Technology contract from Vizient for its Biatain Silicone Fit wound dressing product. The product features 3DFit technology that expands to match wound shape and depth, reducing waste and improving clinical efficiency. The contract was awarded based on hospital expert review and recognition of the product's potential to enhance healthcare delivery.

05/01/2026, 9:00 AM • GlobeNewswire

Wound Cleanser Products Market Size is Projected to be USD 5.17 Billion by 2035; Industry is Propelling Owing to the Growing Technological Investments Globally

The global wound cleanser products market is valued at USD 3.22 billion in 2025 and is projected to reach USD 5.17 billion by 2035, growing at a CAGR of 4.92%. Growth is driven by rising chronic wounds, surgical procedures, and demand for advanced antimicrobial cleansing solutions. The U.S. market is expected to grow from USD 0.99 billion to USD 1.49 billion during the same period. Saline-based cleansers dominate with 37.55% market share, while antimicrobial cleansers are expected to grow fastest at 6.18% CAGR.

05/01/2026, 6:00 AM • GlobeNewswire

Coloplast A/S - Coloplast revises financial guidance for FY 2025/26 to reflect reduced growth outlook for Kerecis

Coloplast has revised down its FY 2025/26 financial guidance, lowering organic growth expectations from ~7% to 5-6% and EBIT growth from ~7% to ~5%, primarily due to slower-than-expected market recovery in Kerecis skin substitutes following Medicare reimbursement changes. The company recognized a DKK 3.0 billion impairment loss against Kerecis goodwill, reducing its carrying book value from DKK 9 billion to DKK 6 billion.

04/23/2026, 1:50 PM • GlobeNewswire

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Coloplast A/S has announced the appointment of Gavin Wood as the new President and CEO of the company.

03/08/2026, 5:48 PM • GlobeNewswire

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier

Coloplast A/S has announced the appointment of Gavin Wood as the new President and CEO of the company, as communicated in an official announcement classified as inside information.

03/08/2026, 5:48 PM • GlobeNewswire

Coloplast udnævner Gavin Wood som ny CEO

Coloplast's board has announced the appointment of Gavin Wood as new CEO effective May 1, 2026. Wood, a seasoned medtech executive with 20 years at Johnson & Johnson, will replace interim CEO Lars Rasmussen. Wood previously led J&J MedTech EMEA and brings extensive commercial and global leadership experience to the role.

03/04/2026, 1:52 PM • GlobeNewswire

Coloplast appoints Gavin Wood as new CEO

Coloplast has appointed Gavin Wood as President and Chief Executive Officer, effective May 1, 2026. Wood, a seasoned MedTech executive with two decades of experience at Johnson & Johnson and prior roles at Mölnlycke, will replace interim CEO Lars Rasmussen. The Board expressed confidence in Wood's ability to drive growth and deliver on the company's Impact4 strategy.

03/04/2026, 1:52 PM • GlobeNewswire

Coloplast A/S - Regnskabsmeddelelse, Q1 2025/26

Coloplast reported Q1 2025/26 organic growth of 6% and EBIT growth of 3% in fixed exchange rates, with EBIT margin at 26%. The company faced headwinds in its Wound & Tissue Repair segment (Kerecis) due to US Medicare reimbursement changes, while Continence and Urologi segments showed strong performance. Full-year guidance remains unchanged at ~7% organic growth and ~7% EBIT growth.

02/06/2026, 1:30 AM • GlobeNewswire

Coloplast A/S - Interim Financial Report, Q1 2025/26

Coloplast reported Q1 2025/26 organic growth of 6% with EBIT growth of 3% in constant currencies. The company faced headwinds in Ostomy Care due to China weakness and high US baselines, while Continence Care and Interventional Urology showed strong momentum. Kerecis experienced significant sales disruption from Medicare reimbursement changes, prompting a downward revision of full-year guidance from 25% to 10% growth. FY 2025/26 guidance remains unchanged at around 7% organic revenue growth and 7% EBIT growth in constant currencies.

02/06/2026, 1:30 AM • GlobeNewswire

Anti-Biofilm Wound Dressing Market to Hit USD 1.82 Billion by 2033, Due to Increasing Antibiotic Resistance and Sophisticated Infection Control Solutions – SNS Insider

The global anti-biofilm wound dressing market is projected to grow from USD 863.95 million in 2025 to USD 1.82 billion by 2033, at a CAGR of 9.76%. Growth is driven by increasing antibiotic-resistant infections, rising chronic wound cases, and adoption of advanced antimicrobial wound care solutions. North America leads the market with 38.50% share, while Asia-Pacific is the fastest-growing region.

01/23/2026, 9:00 AM • GlobeNewswire

Coloplast announces changes to Executive Leadership Team

Coloplast is making leadership changes, with Dorthe Rønnau leaving the People & Culture function and Tommy Johns retiring from Interventional Urology. Kevin Hardage will be the new Executive Vice President of Interventional Urology, bringing extensive MedTech industry experience.

12/18/2025, 9:00 AM • GlobeNewswire